

Dr. Jitiporn Thammasinda Introduces Bio Asia Pacific 2024, Championing Life Science Innovation and Health Equity

11 September 2024 | News | By Ankit Kankar | ankit.kankar@mmactiv.com

The TCELS CEO introduces key initiatives like the Medical AI Accelerator and strategic collaborations at BITEC, positioning Thailand as a global hub for sustainable healthcare advancements.



The Thailand Center of Excellence for Life Sciences (TCELS) proudly presents **Bio Asia Pacific 2024**, under the theme “**Life Science Technology for Sustainable Health Equity.**” This premier event, hosted at the Bangkok International Trade & Exhibition Centre (BITEC), is set to drive transformative discussions and innovation in the life sciences sector, focusing on equitable healthcare solutions powered by advanced technology.

Dr. **Jitiporn Thammasinda**, CEO of TCELS, highlighted that this year's Bio Asia Pacific 2024 will bring together global and regional leaders from biotechnology, healthcare, and medical innovation sectors to foster collaboration. The conference agenda is packed with groundbreaking activities aimed at positioning Thailand as a global hub for life sciences and health-tech innovation.

Among the key highlights are:

1. **Medical AI Accelerator Program:** A dedicated track focused on the convergence of artificial intelligence and healthcare, aiming to revolutionize diagnostics, treatment planning, and personalized medicine. This program will showcase the latest AI-powered healthcare solutions and explore the potential for scaling AI-driven innovations across Asia-Pacific.
- 2.

Pitching Competition: A platform for emerging biotech and MedTech startups to present their cutting-edge solutions to investors, industry veterans, and policymakers. This initiative will spotlight innovative ideas that address healthcare challenges, promote sustainable health equity, and catalyze new investment opportunities in the sector.

3. **One-on-One Partnering:** This exclusive networking session offers participants the opportunity to engage in focused discussions with potential partners, investors, and collaborators, fostering strategic alliances that can accelerate growth and innovation in life sciences.
4. **MoU Signing Ceremony:** One of the major milestones of Bio Asia Pacific 2024 is the **Memorandum of Understanding (MoU) signing** to establish the **Thailand OECD GLP/Non-OECD GLP Preclinical Testing Network**, marking a significant step toward enhancing Thailand's capabilities in preclinical research and testing. The network will set new standards in compliance with international Good Laboratory Practice (GLP), facilitating innovation in drug development, clinical trials, and biosafety regulations.

Dr. Jitiporn stated, *"The establishment of the OECD GLP Preclinical Testing Network will propel Thailand into the global preclinical research stage, allowing us to support advanced testing and compliance services for both domestic and international clients. This will not only improve research capabilities but also attract foreign investment and collaboration in life sciences."*

With a focus on promoting life science technologies that foster sustainable health equity, Bio Asia Pacific 2024 provides a robust platform for stakeholders to explore innovations that bridge the gap between technology and healthcare accessibility, aligning with Thailand's broader commitment to sustainable development.

The event promises to be a dynamic confluence of technology, research, and policy development that will fuel growth in Thailand's life sciences sector and expand its reach in the global market.